trial
as of 2026-07-01Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
NCTId NCT00768612
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2009-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-11
Primary completion
2009-07
Eligibility
ALL · 20 Years · 65 Years
Interventions & indications
Sponsors
Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor
Sites
0 total
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2009-07
Status
WITHDRAWN
relationships
The graph out of here
drug
lead_sponsor
indication
indication
indication